Liquichek Tumor Marker Control-Level 1; Liquichek Tumor Marker Control-Level 2; Liquichek Tumor Marker Control-Level 3; Liquichek Tumor Marker Control- Trilevel MiniPak

K163015 · Bio-Rad Laboratories · JJY · Jan 10, 2017 · Clinical Chemistry

Device Facts

• Record ID: K163015
• Device Name: Liquichek Tumor Marker Control-Level 1; Liquichek Tumor Marker Control-Level 2; Liquichek Tumor Marker Control-Level 3; Liquichek Tumor Marker Control- Trilevel MiniPak
• Applicant: Bio-Rad Laboratories
• Product Code: JJY · Clinical Chemistry
• Decision Date: Jan 10, 2017
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.1660
• Device Class: Class 1

Indications for Use

Liquichek Tumor Marker Control is intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert. The following analytes are listed in the package insert: - Alpha Fetoprotein (AFP) - Beta-2-Microglobulin (B2-M) - CA 15-3 - CA 19-9 - CA 27.29 - CA 125 - Carcinoembryonic Antigen (CEA) - Ferritin - Her-2/neu - Human Chorionic Gonadotropin (hCG)/(β-hCG, Total hCG, Intact hCG) - Human Epididymis Protein (HE4) - Insulin-like Growth Factor-I (IGF-1) - Prostatic Acid Phosphatase (PAP) - Prolactin - Prostate Specific Antigen, Total (Total PSA) - Prostate Specific Antigen, Free (Free PSA) - Thyroglobulin (Tg)

Device Story

Liquichek Tumor Marker Control is an assayed quality control serum; used by clinical laboratories to monitor precision of testing procedures for various tumor marker analytes. Product is prepared from human serum with added constituents of human/animal origin, stabilizers, and preservatives. Provided in liquid form in three levels or a trilevel minipak. Laboratory personnel use the control to verify assay performance; results are compared against provided value assignment charts to ensure testing accuracy. The modification adds Her-2/neu and HE4 to the existing analyte panel. Benefits include standardized quality monitoring for clinical diagnostic assays.

Clinical Evidence

No clinical data. Bench testing only. Stability studies (real-time and accelerated) were performed to establish shelf-life, thawed, and open-vial stability for the added analytes. Protocols and acceptance criteria were reviewed and found acceptable.

Technological Characteristics

Liquid quality control serum; human source material with animal-derived constituents, chemicals, stabilizers, and preservatives. Analyte list includes AFP, B2-M, CA 15-3, CA 19-9, CA 27.29, CA 125, CEA, Ferritin, Her-2/neu, hCG, HE4, IGF-1, PAP, Prolactin, Total PSA, Free PSA, and Thyroglobulin. Storage: -20°C to -70°C.

Indications for Use

Indicated for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for tumor marker analytes in clinical laboratory settings.

Regulatory Classification

Identification

A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.

Predicate Devices

• Liquichek Tumor Marker Control (K071675)

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number:
K163015

B. Purpose for Submission:
Modification of previously cleared control (K071675) to add Her-2/neu and Human Epididymis Protein (HE4)

C. Measurand:
Multi-analyte quality control materials

D. Type of Test:
Not applicable

E. Applicant:
Bio-Rad Laboratories

F. Proprietary and Established Names:
- Liquichek Tumor Marker Control – Level 1
- Liquichek Tumor Marker Control – Level 2
- Liquichek Tumor Marker Control – Level 3
- Liquichek Tumor Marker Control – Trilevel Minipak

G. Regulatory Information:
1. Regulation section:
21 CFR 862.1660, Quality control material (assayed and unassayed)
2. Classification:
Class I, Reserved
3. Product code:
JJY

{1}

4. Panel:
Chemistry (75)

H. Intended Use:

1. Intended use:

Liquichek Tumor Marker Control is intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert.

The following analytes are listed in the package insert:
- Alpha Fetoprotein (AFP)
- Beta-2-Microglobulin (B2-M)
- CA 15-3
- CA 19-9
- CA 27.29
- CA 125
- Carcinoembryonic Antigen (CEA)
- Ferritin
- Her-2/neu
- Human Chorionic Gonadotropin (hCG)/(β-hCG, Total hCG, Intact hCG)
- Human Epididymis Protein (HE4)
- Insulin-like Growth Factor-I (IGF-1)
- Prostatic Acid Phosphatase (PAP)
- Prolactin
- Prostate Specific Antigen, Total (Total PSA)
- Prostate Specific Antigen, Free (Free PSA)
- Thyroglobulin (Tg)

2. Indication(s) for use:
See Intended use above.

3. Special conditions for use statement(s):
For prescription use only.

4. Special instrument requirements:
See product insert for instruments' requirements.

I. Device Description:

Liquichek Tumor Marker Control is prepared from human serum with added constituents of

2

{2}

human and animal origin, stabilizers and preservatives. This product is provided in liquid form for convenience in the following configurations:

| Description | Configuration |
| --- | --- |
| Liquichek Tumor Marker Control, Level 1 | 6 x 2 mL |
| Liquichek Tumor Marker Control, Level 2 | 6 x 2 mL |
| Liquichek Tumor Marker Control, Level 3 | 6 x 2 mL |
| Liquichek Tumor Marker Control, Trilevel MiniPak | 3 x 2 mL(1 per level) |

The sponsor has the following caution statement in their labeling: "The human source material used to manufacture this control was tested by FDA accepted methods and found non-reactive for Hepatitis B Surface Antigen (HBsAg), antibody to Hepatitis C (HCV) and antibody to HIV-1/HIV-2." The labeling also includes the standard precaution about proper handling of human-sourced material cautions.

# J. Substantial Equivalence Information:

1. Predicate device name and 510(k) number:

Liquichek Tumor Marker Control, K071675

3. Comparison with predicate:

| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Intended Use | Liquichek Tumor Marker Control is intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert. | Same |
| Form | Liquid | Same |
| Base Matrix | Human source material and constituents of animal origin | Same |
| Thawed and Open Stability | All analytes at 60 days at 2–8°C Except: • IGF-1, PAP: 35 days at 2–8°C • Free PSA: 30 days at 2–8°C | Same |

{3}

| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| | • CA 125: 14 days at 2–8°C | |
| Frozen Aliquot Stability | 30 days at -20–-70°C | Same |
| Shelf Life | 36 months at -20–-70°C | Same |
| Differences | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Frozen aliquot | 30 days at -20–-70 °C | No claim |
| Analytes | Contains: | Contains: |
| | • Alpha Fetoprotein (AFP)
• Beta-2-Microglobulin (B2-M)
• CA 15-3
• CA 19-9
• CA 27.29
• CA 125
• Carcinoembryonic Antigen (CEA)
• Ferritin
• Her-2/neu
• Human Chorionic Gonadotropin (hCG)/(β-hCG, Total hCG, Intact hCG)
• Human Epididymis Protein (HE4)
• Insulin-like Growth Factor-I (IGF-1)
• Prostatic Acid Phosphatase (PAP)
• Prolactin
• Prostate Specific Antigen, Total (Total PSA)
• Prostate Specific Antigen, Free (Free PSA)
• Thyroglobulin (Tg) | • Alpha Fetoprotein (AFP)
• Beta-2-Microglobulin (B2-M)
• CA 15-3
• CA 19-9
• CA 27.29
• CA 125
• Carcinoembryonic Antigen (CEA)
• Ferritin
• Human Chorionic Gonadotropin (hCG)/(β-hCG, Total hCG, Intact hCG)
• Insulin-like Growth Factor-I (IGF-1)
• Prostatic Acid Phosphatase (PAP)
• Prolactin
• Prostate Specific Antigen, Total (Total PSA)
• Prostate Specific Antigen, Free (Free PSA)
• Thyroglobulin (Tg) |
| | | Does not contain Her-2/neu and HE4 |

{4}

5

K. Standard/Guidance Document Referenced:

Not applicable

L. Test Principle:

Not applicable

M. Performance Characteristics:

1. Analytical performance:

a. Precision/Reproducibility:

Not applicable.

b. Linearity/assay reportable range:

Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The mean values and corresponding ± 3 standard deviation ranges in the Assignment of Values Data Charts were derived from replicate analyses by different clinical laboratories using Bio-Rad’s protocol or by manufacturers’ using their own value assignment protocols; each value is specific for this lot of product and clinical analyzer. The tests listed were performed by the manufacturer and/or independent laboratories using manufacturer supported reagents and a representative sampling of this lot of product. It is recommended that each laboratory establish its own acceptable ranges and use those provided only as guides.

Stability Studies:

Real-time stability studies were performed to establish thawed stability claims. Thawed and open-vial stability when stored at 2°C–8°C is as follows: IGF-1 is 15 days, CA 125 is 10 days, and all other analytes are 30 days.

Thawed and unopened-vial stability when stored at 2°C–8°C is as follows: IGF-1 is 35 days, free PSA is 30 days, CA 125 is 14 days, and all other analytes are 60 days.

Frozen aliquot stability is 30 days when stored at −20°C–−70°C for all analytes.

Accelerated stability studies were performed for establishing the shelf life claim of 28 months from the date of manufacture when stored at −20°C–−70°C. Real time studies are ongoing, and support 10 months stability at this writing.

{5}

Shelf-life and open-vial stability studies protocols and acceptance criteria were reviewed and found to be acceptable.

d. Detection limit:
Not applicable

e. Analytical specificity:
Not applicable

f. Assay cut-off:
Not applicable

2. Comparison studies:
a. Method comparison with predicate device:
Not applicable
b. Matrix comparison:
Not applicable

3. Clinical studies:
a. Clinical Sensitivity and Specificity:
Not applicable
b. Other clinical supportive data (when a. not applicable):

4. Clinical cut-off:
Not applicable

5. Expected values/Reference range:
Not applicable

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

6

{6}

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

7